The Life Sciences team advised Kriya Therapeutics on its $80.5 million Series A financing.
Kriya is a next-generation gene therapy company focused on the engineering and development of transformative gene therapies for highly prevalent diseases. The company plans to use the proceeds from the financing to build its internal GMP manufacturing infrastructure, advance its research platform technologies, and develop its pipeline of rationally engineered gene therapies.
Investors in the round included QVT Financial, Dexcel Pharma, CRS Capital, Foresite Capital, Bluebird Ventures (affiliate of Sutter Hill Ventures), Narya Capital, Amplo, PBM Capital, and Asia Alpha. This Series A round comes following an initial seed financing completed by the company in 2019.
The Goodwin team was led by Deepa Rich and Sam Zucker with support by Wynn Stateman and Chris Denn.
For more details, read the press release and articles in BioSpace, FierceBiotech, and Endpoints.
Kriya is a next-generation gene therapy company focused on the engineering and development of transformative gene therapies for highly prevalent diseases. The company plans to use the proceeds from the financing to build its internal GMP manufacturing infrastructure, advance its research platform technologies, and develop its pipeline of rationally engineered gene therapies.
Investors in the round included QVT Financial, Dexcel Pharma, CRS Capital, Foresite Capital, Bluebird Ventures (affiliate of Sutter Hill Ventures), Narya Capital, Amplo, PBM Capital, and Asia Alpha. This Series A round comes following an initial seed financing completed by the company in 2019.
The Goodwin team was led by Deepa Rich and Sam Zucker with support by Wynn Stateman and Chris Denn.
For more details, read the press release and articles in BioSpace, FierceBiotech, and Endpoints.